GlassScriptPhysician profile
Jordan Claboine
NPI 1336706985
$3,945.80
in general payments reported to CMS, 2019-2025
12 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.77 · 2020: $453 · 2021: $267 · 2022: $292 · 2023: $554 · 2024: $863 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727 · Entertainment: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.91 |
| Entertainment | $118.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,272.48 | 2022-2025 | Infuse, Miebo |
| Coopervision INC. | $1,085.08 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Optos, INC. | $268.62 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $220.92 | 2021 | |
| Amgen INC. | $194.70 | 2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $178.41 | 2023-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $171.80 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $153.07 | 2025 | Dailies Total1, Precision7 |
| Glaukos Corporation | $151.59 | 2024 | Radius |
| Dompe US, INC. | $145.47 | 2025 | Oxervate |
| Rxsight INC | $79.72 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Harrow Eye, LLC | $23.94 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Claboine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.